Clinical Trial Detail

NCT ID NCT02429375
Title Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Mocetinostat

Age Groups: adult

No variant requirements are available.